



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Handwritten mark resembling a stylized 'B' or 'D'.

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/265,191	03/10/99	CARSON	D 07340/044002

PAULA A BORDEN
BOZICEVIC, FIELD AND FRANCIS LLP
200 MIDDLEFIELD RD
SUITE 200
MENLO PARK CA 94025

HM22/1205

EXAMINER

NGUYEN, Q

ART UNIT

PAPER NUMBER

1632

Handwritten number 19.

DATE MAILED:

12/05/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Interview Summary

Application No.
09/265,191

Applicant(s)
Carson et al.

Examiner
Quang Nguyen, Ph.D.

Group Art Unit
1632



All participants (applicant, applicant's representative, PTO personnel):

(1) Paula A. Borden

(3) Deborah Crouch

(2) Carol L. Francis

(4) Quang Nguyen

Date of Interview November 28, 2000

Type: ☒ Telephonic ☐ Personal (copy is given to ☐ applicant ☐ applicant's representative).

Exhibit shown or demonstration conducted: ☐ Yes ☒ No. If yes, brief description:

Agreement ☒ was reached. ☐ was not reached.

Claim(s) discussed: All pending claims

Identification of prior art discussed:

Description of the general nature of what was agreed to if an agreement was reached, or any other comments:
Clarification of the Election/Restriction requirement mailed on 09/26/2000 in paper no. 18. The pending claims 85-176 will be renumbered properly as claims 110-201, and the renumbered claims will be referred from now on during the prosecution of this application. It is agreed that claims 110, 111, 118-134, 141-157, 164-180 and 187-201 are the generic claims, with the following species selection: Species 1: Claims 112, 113, 116, 117, 135, 136, 139, 140, 158, 159, 162, 163, 181, 182, 185 and 186 drawn to methods comprising administering an immunostimulatory polynucleotide to a mammal sensitized to an antigen wherein the co-administering antigen is in the form of a polynucleotide; Species 2: Claims 114, 115, 137, 138, 160, 161, 183 and 184 are directed to methods comprising administering an immunostimulatory polynucleotide to a mammal sensitized to an antigen wherein the co-administering antigen is in the form of a polypeptide.

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

1. ☐ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a response to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

2. ☐ Since the Examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the interview unless box 1 above is also checked.

Quang Nguyen
12/4/00

Examiner Note: You must sign and stamp this form unless it is an attachment to a signed Office action.